Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) today signed a licence agreement with Qi Kang Medical, Ltd (QKM), a joint venture between Eckert & Ziegler ...
20251301_ITM and Ariceum Therapeutics Enter Into Supply Agreement for Therapeutic Medical Radioisotope Actinium-225 ...
The Korea Times on MSN18d
Korea to produce cancer treatment actinium-225 domestically by mid-2025Korea is set to begin domestic production of actinium-225 (Ac-225), a key raw material for next-generation cancer treatments, ...
Bill Gates' nuclear power venture, TerraPower Isotopes, has become the first to boost production of a radioactive substance that has shown new promise in the fight against cancer, called actinium ...
(RTTNews) - Actinium Pharmaceuticals Inc. (ATNM) Monday announced a narrower loss for the third quarter. The September quarter loss was $11.6 million, compared to $13.3 million a year ago.
Actinium Pharmaceuticals ( (ATNM)) has released its Q3 earnings. Here is a breakdown of the information Actinium Pharmaceuticals presented to its investors. Actinium Pharmaceuticals, Inc. is a ...
NEW YORK (AP) — NEW YORK (AP) — Actinium Pharmaceuticals Inc. (ATNM) on Thursday reported a loss of $11.6 million in its third quarter. On a per-share basis, the New York-based company said it ...
Ac-SSO110 (satoreotide) is a first in class Actinium-labelled SSTR2 receptor antagonistPhase I/II SANTANA-225 study on track to enrol patients in Q1 2025BERLIN, Jan. 14, 2025 /PRNewswire/ ...
Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, and ITM Isotope Technologies Munich ...
Garching / Munich / Berlin, Germany, January 13, 2025 - ITM Isotope Technologies Munich SE(Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment o ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback